You are here: Industry Insights > Sanofi

News List

Breakthrough Therapy for Type 2 Immune Indications: the Ten Billion dollars drug Dupilumab will be marketed in China PharmaSources/1℃
June 19, 2020
Sanofi explained in detail the mechanism of action of Dupilumab and its clinical benefit in type 2 immune indications at a recent R&D conference.
Sanofi completes acquisition of Amunix WorldPharmaNews
February 10, 2022
Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN...
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines WorldPharmaNews
January 21, 2022
Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology...
Sanofi and Exscientia to develop AI-driven cancer and immunology medicines Pharmaceutical-Technology
January 11, 2022
Sanofi and Exscientia have entered a research partnership and licence agreement for the development of up to 15 new small-molecule medicines across oncology and immunology.
Exscientia and Sanofi establish research collaboration to develop AI-driven precision engineered medicines ExpressPharma
January 10, 2022
Sanofi and Exscientia recently announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology...
Exscientia and Sanofi collaborate to develop AI-driven precision-engineered medicines pharmatimes
January 07, 2022
The platform integrates primary human tissue samples into early target and drug discovery research.
Sanofi to acquire immuno-oncology firm Amunix for $1bn Pharmaceutical-Technology
December 23, 2021
Sanofi has signed an agreement for the acquisition of immuno-oncology firm Amunix Pharmaceuticals for nearly $1bn in upfront payment.
Sanofi to acquire Origimm Biotechnology to develop acne vaccine EuropeanPharmaceuticalReview
December 03, 2021
Sanofi has entered into an agreement to acquire Origimm Biotechnology to add a potential first-in-class vaccine for acne to their pipeline.
Sanofi agrees to buy Austria-based Origimm Biotechnology Pharmaceutical-Business-Review
December 02, 2021
Sanofi has signed an agreement to buy Origimm Biotechnology, an Austria-based privately owned biotechnology company with focus on virulent skin microbiome components and antigens from bacteria causing skin disease.
Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline WorldPharmaNews
December 02, 2021
Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page